A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. by Inman, Brant A et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Radiation Oncology Faculty Papers Department of Radiation Oncology
5-2014
A pilot clinical trial of intravesical mitomycin-C and
external deep pelvic hyperthermia for non-muscle-
invasive bladder cancer.
Brant A Inman
Duke University Medical Center
Paul R. Stauffer
Thomas Jefferson University, paul.stauffer@jefferson.edu
Oana A Craciunescu
Duke University Medical Center
Paolo F Maccarini
Duke University Medical Center
Mark W Dewhirst
Duke University Medical Center
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/radoncfp
Part of the Oncology Commons, and the Radiology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Radiation Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please
contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Inman, Brant A; Stauffer, Paul R.; Craciunescu, Oana A; Maccarini, Paolo F; Dewhirst, Mark W; and
Vujaskovic, Zeljko, "A pilot clinical trial of intravesical mitomycin-C and external deep pelvic
hyperthermia for non-muscle-invasive bladder cancer." (2014). Department of Radiation Oncology
Faculty Papers. Paper 52.
http://jdc.jefferson.edu/radoncfp/52
Authors
Brant A Inman, Paul R. Stauffer, Oana A Craciunescu, Paolo F Maccarini, Mark W Dewhirst, and Zeljko
Vujaskovic
This article is available at Jefferson Digital Commons: http://jdc.jefferson.edu/radoncfp/52
A pilot clinical trial of intravesical mitomycin-C and external
deep pelvic hyperthermia for non-muscle-invasive bladder
cancer
Brant A. Inman1, Paul R. Stauffer2, Oana Craciunescu3, Paolo F. Maccarini3, Mark W.
Dewhirst3, and Zeljko Vujaskovic4
1Division of Urology, Duke University Medical Center, Durham, North Carolina
2Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania
3Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
4Department of Radiation Oncology, University of Maryland, Maryland, USA
Abstract
Purpose—This paper aims to evaluate the safety and heating efficiency of external deep pelvic
hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-
invasive bladder cancer (NMIBC).
Materials and methods—We enrolled subjects with bacillus Calmette-Guérin (BCG)
refractory NMIBC to an early phase clinical trial of external deep pelvic hyperthermia (using a
BSD-2000 device) combined with MMC. Bladders were heated to 42 °C for 1 h during
intravesical MMC treatment. Treatments were given weekly for 6 weeks, then monthly for 4
months. Heating parameters, treatment toxicity, and clinical outcomes were systematically
measured.
Results—Fifteen patients were enrolled on the clinical trial. Median age was 66 years and 87%
were male. Median European Organisation for Research and Treatment of Cancer (EORTC)
recurrence and progression scores were 6 and 8, respectively. The full treatment course was
attained in 73% of subjects. Effective bladder heating was possible in all but one patient who
could not tolerate the supine position due to lung disease. Adverse events were all minor (grade 2
or less) and no systemic toxicity was observed. The most common adverse effects were Foley
catheter pain (40%), abdominal discomfort (33%), chemical cystitis symptoms (27%), and
abdominal skin swelling (27%). With a median follow-up of 3.18 years, 67% experienced another
bladder cancer recurrence (none were muscle invasive) and 13% experienced an upper tract
recurrence.
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Conclusions—External deep pelvic hyperthermia using the BSD-2000 device is a safe and
reproducible method of heating the bladder in patients undergoing intravesical MMC. The efficacy
of this treatment modality should be explored further in clinical trials.
Keywords
Bladder cancer; clinical trial; hyperthermia; mitomycin C
Introduction
Bladder cancer is the fourth most common type of cancer in men and the ninth most
common cancer in women in the USA [1]. The most common type of bladder cancer,
urothelial carcinoma, originates in cells lining the inside of the bladder and accounts for
~90% of all bladder cancers. Bladder cancers are staged according to a standard tumour,
lymph node, and metastasis (TNM) staging system: Ta – non-invasive, T1 – invasive into
lamina propria, T2 – invasive into muscularis propria, T3 – invasive into perivesical fat, and
T4 – invasive into adjacent organs. Two broad clinical phenotypes of bladder cancer exist:
non-muscle-invasive bladder cancer (NMIBC) (Ta, T1) and muscle invasive bladder cancer
(T2, T3, T4) and each are managed differently [2].
A fundamental characteristic of NMIBC is a very high local recurrence rate, ranging from
40–80%, depending on individual prognostic factors. An important goal in managing
NMIBC is reducing the risk of bladder cancer recurrences, which can occur repeatedly over
many years, leading to multiple surgical interventions and high healthcare costs. The
application of intravesical chemotherapy, whether given in the operating room immediately
following transurethral tumour resection or adjuvantly using a weekly dosing scheme, has
been shown to reduce the recurrence rate of bladder cancer [3,4]. Unfortunately, intravesical
chemotherapy does not eliminate the risk of recurrence and at least a third of subjects treated
with intravesical chemotherapy will still recur. One strategy that has been shown to increase
the efficacy of intravesical chemotherapy is bladder hyperthermia, a treatment where the
bladder is heated to enhance the effectiveness of the chemotherapeutic agent filling the
bladder [5–7]. Hyperthermia has numerous effects on the tumour micro-environment [8], but
the most important known effect in bladder cancer is that it makes existing bladder
chemotherapies more effective. Specifically, a number of European clinical trials have
shown that moderate hyperthermia (42–44 °C) improves the efficacy of intravesical
mitomycin C (MMC), the most commonly used intravesical chemotherapy agent [9].
Combined hyperthermia and mitomycin C has not, to our knowledge, been studied clinically
in North America and the current study is the first to do so.
Bladder heating can be achieved in different ways, including by radiofrequency-emitting
intravesical catheters, by circulation of externally heated chemotherapy fluid into the
bladder, by exciting intravesical magnetic nanoparticles within a magnetic field, and with
external deep pelvic radiofrequency transmission [9]. External deep pelvic hyperthermia has
been used in combination with radiation therapy to treat pelvic malignancies and has been
shown to be an effective of heating pelvic organs [10], but it has never been employed to our
knowledge in combination with intravesical therapy for treating bladder cancer. Deep pelvic
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hyperthermia is accomplished in the current clinical trial using a phased array of external
radiofrequency antennas that deposit energy within the pelvis and are focused primarily on
the bladder. In this clinical trial, we explored intravesical mitomycin C combined with
external deep pelvic hyperthermia for the treatment of bacillus Calmette-Guérin (BCG)
refractory NMIBC as a novel way of combining hyperthermia with intravesical therapy. We
hypothesised that this treatment regimen would result in effective bladder heating and would
be tolerable to the patient and would occur with minimal toxicity.
Patients and methods
Subjects
This clinical trial was designed to assess the safety and tolerability of external deep pelvic
hyperthermia combined with intravesical MMC to treat BCG refractory NMIBC. Eligibility
criteria included age ≥18 years, urothelial carcinoma with TNM stage Ta, T1, or Tis, a
minimum 2-week interval since transurethral resection of bladder tumour (TURBT), and an
Eastern Clinical Oncology Group (ECOG) performance status ≤2. Additionally, subjects
were required to have completed a 6-week induction course of BCG prior to their most
recent bladder cancer recurrence or be intolerant of BCG. Subjects were excluded if any of
the following were present: history of pelvic radiation, pregnancy or breastfeeding, bleeding
diathesis, hypersensitivity to MMC, pacemaker or related electrical devices, hip prostheses
or other implanted pelvic hardware, uncontrolled hypertension, severe respiratory disease
that precluded supine positioning or abdominal compression, or severe peripheral
neuropathy. All subjects underwent urine cytology, cystoscopy and CT urography within 8
weeks of enrolment to rule out prevalent upper urinary tract, bladder, or urethral tumours.
The protocol was approved by the Duke Institutional Review Board (IRB) and registered at
www.clinicaltrials.gov (NCT00734994) under IDE G030263. Eligible subjects provided
written informed consent and accrual occurred between November 2008 and August 2010.
Intravesical therapy and treatment schedule
An induction course of intravesical MMC (40 mg diluted in 40 mL of sterile water) was
administered once weekly for 6 weeks [11]. The MMC dwell time was at least 60 min but
no more than 120 min in duration, of which 40 min but no more than 60 min had to occur at
a temperature of 42° ± 2 °C. Cystoscopy and urine cytology tests were performed 6 weeks
after completion of induction and, if no evidence of bladder cancer recurrence was noted in
either test, maintenance MMC was administered consisting of monthly intravesical MMC
given for an additional 4 months [12,13]. Therefore, a maximum of 10 treatments of
combination MMC and hyperthermia was possible under the protocol. At each intravesical
treatment, an 18 F 3-way Foley catheter was inserted into the bladder, the bladder drained of
urine, a bladder thermistor placed, MMC instilled, and bladder heating started.
External deep pelvic hyperthermia
Deep pelvic hyperthermia was achieved with a BSD-2000 device with Sigma-Ellipse or
Sigma 60 applicator (BSD Medical, Salt Lake City, UT). Using either applicator, the system
consists of an external phased array of four twin dipole antennas mounted concentrically
around the torso and coupled with a distilled water bolus to deliver radiofrequency waves
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within a range of 80–120 MHz to produce a steerable focal region within the pelvis. A
planning CT scan was obtained prior to treatment and device settings determined using a
hyperthermia planning system. The treatment goal was an intravesical temperature of 42° ±
2 °C that was to be maintained for 40–60 min and initial applicator settings were manually
adjusted during treatment based on real-time input from skin surface and intracavitary
(bladder and rectum) temperature sensors. Full details of the thermal dosimetry and
treatment planning methods used in this clinical trial are described elsewhere [6].
Bladder surveillance and treatment toxicity assessment
Subjects were followed according to NCCN Clinical Practice Guidelines in Oncology for
Bladder Cancer (version 2.2008, www.nccn.org) for high risk NMIBC. This consisted of
cystoscopy and urine cytology every 3 months for 2 years, then every 6 months for 2 years,
then annually thereafter. Routine upper tract imaging was not required by the study protocol
but was generally performed if recurrent disease was noted in the bladder or if urine
cytology was positive in a subject with negative cystoscopy. All suspicious lesions detected
during surveillance were biopsied to confirm local disease recurrence, which was defined as
the histological presence of urothelial carcinoma in the bladder. Recurrence of urothelial
carcinoma in the upper urinary tracts or urethra was also recorded and was considered non-
local disease recurrence. Progression was defined as the development of muscle-invasive
bladder cancer or urothelial carcinoma metastases to lymph nodes or other solid organs.
Recurrent tumours were graded using the World Health Organization/International Society
of Urological Pathology (ISUP) system and staged with the 2010 TNM system [2,14].
Treatment toxicity was assessed at each treatment session and at each clinical surveillance
visit and graded using the Common Terminology Criteria for Adverse Events (CTCAE),
version 3.0. Toxicities occurring outside of routine follow-up were also captured.
Statistical methods
This was a pilot clinical trial to assess the safety and feasibility of combining deep external
pelvic hyperthermia to intravesical MMC. The primary objective was to determine the
ability of the BSD-2000 device to heat the bladder to the desired temperature and to
determine the incidence of treatment-related toxicity. The secondary objective was to
determine the cumulative incidence of bladder cancer recurrence and progression at 2 years,
and as such, all subjects were followed until recurrence or until a minimum of two post-
treatment years had elapsed. The statistical plan called for up to 18 subjects to be enrolled in
the trial for a total of 15 evaluable subjects. Clinical variables were described using
proportions if categorical, and using medians and their interquartile range if continuous.
Bladder cancer recurrences and the occurrence of radical cystectomy were measured using
cumulative incidence functions [15]. Statistical analyses were done using R 3.0.1 with
packages cmprsk and survival installed [16].
Results
A total of 18 subjects were approached for enrolment in the clinical trial. Of these, 15 met
all eligibility criteria and consented to the clinical trial. Baseline clinical characteristics of
the study population are shown in Table I. As the table demonstrates, the study population
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consisted of subjects that had experienced multiple prior transurethral bladder cancer
resections and all had experienced at least one recurrence following prior BCG therapy.
High risk features for recurrence and/or progression – such as the presence of CIS, T1
lamina propria invasion, high grade cytology, or an elevated prior recurrence rate – were
present in all subjects. Using the EORTC bladder cancer risk prediction tools [17], 86% of
subjects were deemed to be at high or very high risk of recurrence and 80% were at high or
very high risk of progression.
The full treatment course (six induction sessions + four maintenance sessions) was achieved
in 11 (73%) subjects. One subject withdrew from the study after undergoing a single attempt
at treatment due to an inability to tolerate the supine position as a result of severe chronic
obstructive pulmonary disease. Three subjects received the full induction course but were
withdrawn from the study prior to receiving all four maintenance sessions due to cancer
recurrences detected at the first post-induction surveillance cystoscopy. The heating time
required to achieve 42 °C was 10–15 min.
Adverse events are summarised in Table II. The most common adverse events were minor
urethral discomfort from Foley catheter placement (40%), minor abdominal discomfort from
the hyperthermia device (33%), irritative urinary symptoms from chemical cystitis (27%),
and heat-induced minor swelling of the abdominal skin (27%). No grade 3 or greater
toxicities were observed and no subject discontinued therapy due to adverse events.
With a median follow-up from study enrolment to last visit of 3.18 years, 10 (67%) subjects
experienced recurrent bladder cancer, with a median time to recurrence of 15.4 months, but
none of these recurrences consisted of progression events to detrusor muscle invasion. The
cumulative incidence of recurrences is shown in Figure 1(A). Of the 10 subjects that
recurred with bladder cancer, six (60%) underwent radical cystectomy at a median time of
20.1 months from study enrolment. Pathological stage at cystectomy was pTis in five
subjects, pT1 in one subject, and pelvic nodes were negative in all patients (median node
count = 15). The cumulative incidence of cystectomy is shown in Figure 1(B). Three
subjects with recurrent bladder cancer (30%) refused cystectomy and underwent alternative
intravesical regimens and none has experienced disease progression. Two subjects (13%)
developed upper urinary tract recurrences and these occurred at a median time from
enrolment of 18.7 months. Both of these individuals were treated for their upper urinary
tract cancer but ultimately developed metastases and died from their disease. One patient
(7%) died from causes unrelated to cancer.
Discussion
Patients with BCG-refractory NMIBC are in a difficult conundrum [18]. On the one hand,
their disease state does not normally carry an imminent risk of metastasis and death, but on
the other hand, it can progress (usually over years) into a muscle-invasive disease state that
certainly does carry this risk. The most widely accepted treatment for BCG-refractory
NMIBC that reduces the risk of progression and results in a very high probability of cure is
radical cystectomy. Unfortunately, radical cystectomy is a morbid surgical procedure that is
associated with permanent quality of life changes and also a non-negligible treatment-related
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mortality rate [19]. Additionally, it is costly and has a very high perioperative complication
rate. Patients and their doctors must therefore decide between taking a risky treatment that
causes some degree of permanent disability and loss of quality of life but that is likely
curative, or choose to observe the cancer and run the risk of it progressing to a state where it
is no longer curable.
This difficult clinical dilemma is why there is a clear need for less invasive alternatives to
radical cystectomy for patients with NMIBC that continues to recur despite standard first-
line BCG therapy. In this respect, second-line intravesical therapies are certainly the most
commonly explored alternatives to radical cystectomy. Mitomycin C [20], gemcitabine [20],
paclitaxel [21], interferon-α2B [22], valrubicin [23], apaziquone [24] and several other
agents have been studied in this context, and all have been found to be suboptimal in their
ability to prevent disease recurrence and progression. Methods of improving the delivery of
these agents have therefore been investigated and device-assisted instillation methods such
as electromotive administration and hyperthermia have been the most successful [9,25].
Bladder hyperthermia can be achieved in several ways but the intravesical radiofrequency
antenna catheter (i.e. the Synergo device) has been the most studied method to date [26].
In this clinical trial we explored a novel method of performing bladder hyperthermia in
conjunction with intravesical MMC: external deep pelvic hyperthermia. To obtain external
deep pelvic hyperthermia we used a BSD-2000 hyperthermia device and through a process
of thermal modelling and clinical dosimetry were able to develop a method of heating the
bladder and perivesical tissue that was highly reproducible [6]. Additionally, we found this
method of hyperthermia to be associated with not only low toxicity rates but the absence of
any serious (grade 3 or higher) treatment-induced toxicity. Advantages of external deep
pelvic hyperthermia over other methods of hyperthermia include the ability to heat not only
the bladder but the perivesical fat and pelvic lymph nodes, the ability to image the
temperature distribution within the pelvis using 3D MR Sigma Eye thermometry, the
avoidance of bladder hot spots and urothelial burns, and the ability to steer the temperature
distribution and account for variant pelvic anatomy. This means that using the BSD-2000 we
can mould the delivery of hyperthermia to the precise anatomical structures of each
individual patient. Disadvantages of external deep pelvic hyperthermia include a relatively
high start-up equipment cost (approximately US$500 000), difficulties in treating very obese
(BMI>40 kg/m2) patients, and the requirement of maintaining an awake supine position
within a constricting water-bolus aperture. Nevertheless, the procedure was generally well-
tolerated by patients and our results seemed encouraging, particularly since no patient has
progressed to muscle invasion thus far and several patients have noted a significant
reduction in the frequency of their tumour recurrences. Clinical trials of other forms of
hyperthermia combined with MMC have shown an average relative risk reduction (when
compared to MMC alone) of 41% [9]. Additionally, progression rates in these studies ranged
from 0 to 8% [9]. We therefore feel that the current hyperthermia technology merits careful
consideration, particularly with respect to the application of novel heat-activated therapies
that might be systemically delivered and targeted to bladder and lymph nodes.
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Conclusions
External deep pelvic hyperthermia using the BSD-2000 device is a safe and reproducible
method of heating the bladder in patients undergoing intravesical therapy with mitomycin C
for NMIBC. The efficacy of this treatment modality should be explored further in clinical
trials.
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Figure 1.
(A) Cumulative incidence of recurrent bladder cancer and (B) cumulative incidence of radical cystectomy in patients with BCG-
refractory NMIBC undergoing intravesical mitomycin C chemotherapy combined with deep regional pelvic hyperthermia.
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Table I
Baseline clinical characteristics of the study population.
Gender
 Male 13 87%
 Female 2 13%
Age (median) 66 IQR: 56.5–75.0
ECOG performance status
 0 10 67%
 1 5 33%
Charlson score (median) 3 IQR: 2–3.5
Smoking history
 Current or former smoker 11 73%
 Pack-years exposure1 (median number) 34 IQR: 3–60
Urothelial carcinoma history
 Prior recurrences (median number) 3 IQR: 3–5
 Prior CIS 11 73%
 Prior T1 tumour 4 27%
 Prior high grade tumour 8 53%
 Prior urethral tumour 1 7%
 Prior upper tract tumour 1 7%
EORTC recurrence score
 Median 6 IQR: 5–8
 0 (low risk) 0 0%
 1–4 (intermediate risk) 2 13%
 5–9 (high risk) 11 73%
 10–17 (very high risk) 2 13%
EORTC progression score
 Median 8 IQR: 7–14
 0–1 (low risk) 0 0%
 2–6 (intermediate risk) 3 20%
 7–13 (high risk) 8 53%
 14–23 (very high risk) 4 27%
Prior intravesical therapy
 BCG doses (median number) 9 IQR: 6–12
 Mitomycin C 1 7%
 Vicinium (VB4-845) clinical trial 1 7%
IQR, interquartile range.
1Only subjects with a smoking history are included in this calculation.
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Table II
Treatment-associated adverse events.
Adverse event category Grade 1 Grade 2 Total
General
 Abdominal pain 3 (20%) 2 (13%) 5 (33%)
 Fatigue 2 (13%) – 2 (13%)
 Heat intolerance – 1 (7%) 1 (7%)
 Myalgia 1 (7%) – 1 (7%)
Genitourinary
 Urethral pain 6 (40%) – 6 (40%)
 Chemical cystitis 1 (7%) 3 (20%) 4 (27%)
 Haematuria 3 (20%) – 3 (20%)
 Bladder spasm 1 (7%) 1 (7%) 2 (13%)
 Weak urinary stream 1 (7%) – 1 (7%)
 Vaginitis – 1 (7%) 1 (7%)
Gastrointestinal
 Nausea or vomiting 1 (7%) 1 (7%) 2 (13%)
 Constipation 1 (7%) – 1 (7%)
Dermatologic
 Induration/swelling 2 (7%) 2 (13%) 4 (27%)
 Pruritis 3 (20%) – 3 (20%)
 Rash 2 (13%) – 2 (13%)
 Bruising – 1 (7%) 1 (7%)
 Flushing 1 (7%) – 1 (7%)
Neurologic
 Dizziness 2 (13%) – 2 (13%)
 Confusion – 1 (7%) 1 (7%)
 Anxiety 1 (7%) – 1 (7%)
 Extrapyramidal symptoms 1 (7%) – 1 (7%)
Infectious
 Urinary tract infection – 2 (13%) 2 (13%)
Cardiovascular
 Hypertension 3 (20%) – 3 (20%)
No grade 3 or higher complications were observed.
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